Loading...
Phase I/II study of erlotinib, carboplatin, pemetrexed, and bevacizumab in chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer harboring epidermal growth factor receptor mutation
BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors significantly prolong the progression-free survival of patients with non-squamous non-small cell lung cancer (NSCLC). However, most patients develop tumor regrowth and their prognosis remains poor. A new treatment strategy for N...
Na minha lista:
| Udgivet i: | Genes Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Impact Journals LLC
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5511889/ https://ncbi.nlm.nih.gov/pubmed/28740574 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/genesandcancer.145 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|